High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 926-929

  de Souza Cavalcanti, Jaqueline ^a   de Paula Ferreira, João Leandro ^a   de Souza Guimarães, Paula Morena ^a   Vidal, Jose Ernesto ^b   de Macedo Brigido, Luis Fernando ^a  

^a INSTITUTO ADOLFO LUTZ   (Brazil)

^b INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

Author keywords

Antiretroviral resistance; Brazil; HIV; Integrase inhibitors

Indexed keywords

DOLUTEGRAVIR; RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD SAMPLING; CROSS RESISTANCE; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENOTYPING TECHNIQUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VIREMIA; VIRUS LOAD; ANTIVIRAL RESISTANCE; CLASSIFICATION; DNA SEQUENCE; DRUG EFFECTS; GENETICS; GENOTYPE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MISSENSE MUTATION; PROCEDURES; SALVAGE THERAPY; TREATMENT FAILURE; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PYRROLIDINONES; SALVAGE THERAPY; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; YOUNG ADULT;

EID: 84928197536     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku439     Document Type: Article

References (15)

1. Raffi F, Rachlis A, Stellbrink H et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735-43.
2. Walmsley SL, Antela A, Clumeck N et al. Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection. New Engl J Med 2013; 369: 1807-18.
3. Clotet B, Feinberg J, van Lunzen J et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383: 2222-31.
4. Cahn P, Pozniak AL, Mingrone H et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV:week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013; 382: 700-8.
5. Castagna A, Maggiolo F, Penco G et al. Dolutegravir in antiretroviralexperienced patients with raltegravir- and/or elvitegravir-resistant HIV-1:24-week results of the phase III VIKING-3 study. J Infect Dis 2014; 210: 354-62.
6. Kobayashi M, Yoshinaga T, Seki Tet al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55: 813-21.
7. Seki T, Kobayashi M, Wakasa-Morimoto C et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones. In: Abstracts of the Seventeenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2010. Abstract 555. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
8. Quashie PK, Mespléde T, Han YS et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012; 86: 2696-705.
9. de Souza Cavalcanti J, de Paula Ferreira JL, Vidal JE et al. HIV-1-infected patients with advanced disease failing a raltegravir-containing salvage regimen in São Paulo, Brazil. Int J Antimicrob Agents 2014; 43: 287-91.
10. Marcelin AG, Delaugerre C, Beaudoux C et al. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir:factors associated with virological response and mutations selected at failure. Int J Antimicrob Agents 2013; 42: 42-7.
11. Wensing AM, Calvez V, Günthard HF et al. 2014 update of the drug resistance mutations in HIV-1. Top Antivir Med 2014; 22: 642-50.
12. Delelis O, Malet I, Na L et al. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucl Acids Res 2009; 37: 1193-201.
13. Souza Cavalcanti J, Minhoto Lança A, de Paula Ferreira JL et al. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen. Antiviral Res 2012; 95: 9-11.
14. Malet I, Gimferrer Arriaga L, Artese A et al. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemother 2014; 69: 2118-22.
15. Saladini F, Meini G, Bianco C et al. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients. Clin Microbiol Infect 2012; 18: E428-30.